These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 3266874)

  • 41. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
    Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatic arterial infusion of interleukin-2 in advanced hepatocellular carcinoma.
    Yamamoto M; Iizuka H; Fujii H; Matsuda M; Miura K
    Acta Oncol; 1993; 32(1):43-51. PubMed ID: 8385472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interleukin-2 and lymphokine activated killer cells: promises and cautions.
    Glassman AB
    Ann Clin Lab Sci; 1989; 19(1):51-5. PubMed ID: 2644890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
    Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A case of malignant hemangioendothelioma effectively treated with intra-arterial continuous infusion of interleukin-2].
    Fujioka A; Sezai Y
    Nihon Hifuka Gakkai Zasshi; 1991 Aug; 101(9):959-63. PubMed ID: 1942594
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
    Takai N; Tanaka R; Yoshida S; Hara N; Saito T
    Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
    Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
    Cancer Res; 1986 Apr; 46(4 Pt 2):2101-4. PubMed ID: 3512079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
    Puri RK; Leland P
    Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
    Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suppression of lymphokine activated killer (LAK) cells by immunosuppressive substance.
    Hamada F; Fuchimoto S; Orita K
    Res Commun Chem Pathol Pharmacol; 1989 Jul; 65(1):81-95. PubMed ID: 2789420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases.
    Mavligit GM; Zukiwski AA; Gutterman JU; Salem P; Charnsangavej C; Wallace S
    J Clin Oncol; 1990 Feb; 8(2):319-24. PubMed ID: 2405108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 1 beta by interleukin 2.
    Kovacs EJ; Beckner SK; Longo DL; Varesio L; Young HA
    Cancer Res; 1989 Feb; 49(4):940-4. PubMed ID: 2783560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical trials of intrasplenic arterial infusion of interleukin-2 (IS-IL-2) to patients with advanced cancer.
    Okuno K; Ohnishi H; Koh K; Shindo H; Yoshioka H; Yasutomi M
    Biotherapy; 1992; 4(4):257-65. PubMed ID: 1622739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [An experimental study on the in vivo induction of lymphokine activated killer (LAK) cells by the continuous infusion of interleukin 2 (IL-2) through the splenic artery].
    Ohnishi H
    Nihon Gan Chiryo Gakkai Shi; 1988 Dec; 23(11):2785-93. PubMed ID: 3266874
    [No Abstract]   [Full Text] [Related]  

  • 58. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
    Da Pozzo LF; Hough KL; Holder WD
    Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ; Silver HK; Kong S
    Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Augmentation of human lymphokine-activated killer cell activity in splenic lymphocytes by the combination of low-dose interleukin 2 plus interleukin 3.
    Okuno K; Ohnishi H; Shilayama Y; Hirohata T; Ozaki M; Yasutomi M
    Mol Biother; 1992 Jun; 4(2):83-6. PubMed ID: 1515099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.